Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection
Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection: A Prospective Paired Diagnostic Study and a Randomized Controlled Clinical Trial
In this prospective paired diagnostic study and single-center, randomized controlled trial, patients with early esophageal squamous neoplasia or high-grade intraepithelial neoplasia meeting the inclusion and exclusion criteria will be enrolled in a paired diagnostic cohort (60 patients) and subsequently randomly assigned (1:1) to receive endoscopic submucosal dissection (ESD) with AI-based Dissection Trajectory Prediction System (ADTPS) guidance or conventional ESD (without AI). Clinical data and operator workload scores (NASA-TLX) are collected during the procedure, and postoperative follow-up assessments are performed at days 1, 3, 7, and 14. The study aims to analyze the impact of ADTPS on the mean single-dissection time and operator workload in patients undergoing ESD by comparing the efficacy differences between the experimental and control groups. Additionally, the study investigates the effects of ADTPS on other postoperative complications including R0 resection rate, muscularis propria injury, intraoperative bleeding, perforation (acute and delayed), and total procedure time; conducts a comparative analysis of the safety and efficiency of AI-assisted versus conventional ESD; and develops effective clinical strategies for optimizing dissection trajectory and reducing complications in endoscopic submucosal dissection.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Shandong
-
Jinan、Shandong、中国、250012
- 山东大学齐鲁医院
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
prospective paired diagnostic study
Inclusion Criteria:
-
Chinese patients aged 18-80 years.
-
Lesions meeting ESD indications for esophageal, gastric, or colorectal early cancer or high-grade intraepithelial neoplasia, as defined by:
Non-invasive tumors regardless of size; or Differentiated-type intramucosal carcinoma without ulceration, regardless of size; or Differentiated-type intramucosal carcinoma with ulceration and a diameter ≤3 cm; or Undifferentiated-type intramucosal carcinoma without ulceration and a diameter ≤2 cm.Planned to undergo ESD treatment.
-
No prior treatment for the lesion (including ESD, surgery, radiotherapy, chemotherapy, etc.).
-
Platelet count >100 × 10⁹/L and PT-INR <1.5, with antiplatelet agents (aspirin, clopidogrel, etc.) discontinued for at least 5 days.
-
American Society of Anesthesiologists (ASA) physical status grade I or II.
-
Voluntarily signed informed consent.
Exclusion Criteria:
- Patients currently undergoing dialysis.
- Patients with severe cardiopulmonary disease or other severe comorbidities that may increase the risk of the ESD procedure.
- Pregnant or breastfeeding women.
RCT
Inclusion Criteria:
-
Chinese patients aged 18-80 years.
-
Lesions meeting ESD indications for esophageal, gastric, or colorectal early cancer or high-grade intraepithelial neoplasia, as defined by:
Non-invasive tumors regardless of size; or Differentiated-type intramucosal carcinoma without ulceration, regardless of size; or Differentiated-type intramucosal carcinoma with ulceration and a diameter ≤3 cm; or Undifferentiated-type intramucosal carcinoma without ulceration and a diameter ≤2 cm.Planned to undergo ESD treatment.
-
No prior treatment for the lesion (including ESD, surgery, radiotherapy, chemotherapy, etc.).
-
Platelet count >100 × 10⁹/L and PT-INR <1.5, with antiplatelet agents (aspirin, clopidogrel, etc.) discontinued for at least 5 days.
-
American Society of Anesthesiologists (ASA) physical status grade I or II.
-
Voluntarily signed informed consent.
Exclusion Criteria:
- Patients currently undergoing dialysis.
- Patients with severe cardiopulmonary disease or other severe comorbidities that may increase the risk of the ESD procedure.
- Pregnant or breastfeeding women.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:Conventional ESD without AI
|
The same endoscopic hardware platform is used, but the AI-based Dissection Trajectory Prediction System (ADTPS) is turned off. The endoscopist performs the ESD procedure based solely on clinical judgment and personal experience, following standard conventional ESD steps including marking, injection, circumferential incision, and submucosal dissection. |
|
実験的:AI-assisted ESD with ADTPS
|
The ADTPS is an artificial intelligence software system that analyzes endoscopic images in real time during ESD. It automatically identifies lesion boundaries and generates a recommended dissection trajectory overlaid on the endoscopic view. The endoscopist follows the AI-generated trajectory to perform submucosal dissection. The system provides visual guidance only and does not alter the standard surgical workflow. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
NASA-TLX Workload Score
時間枠:Immediately after the ESD procedure
|
Immediately after the ESD procedure
|
|
Mean Single Dissection Time
時間枠:During the ESD procedure
|
During the ESD procedure
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
R0 Resection Rate
時間枠:At the time of pathological examination
|
At the time of pathological examination
|
|
Muscularis Propria Injury Rate
時間枠:During the ESD procedure
|
During the ESD procedure
|
|
Intraoperative Bleeding Episodes
時間枠:During the ESD procedure
|
During the ESD procedure
|
|
Intraoperative Perforation Rate
時間枠:During the ESD procedure
|
During the ESD procedure
|
|
Delayed Bleeding Rate
時間枠:Within 14 days after procedure
|
Within 14 days after procedure
|
|
Delayed Perforation Rate
時間枠:Within 14 days after procedure
|
Within 14 days after procedure
|
|
Total Procedure Time
時間枠:During the ESD procedure
|
During the ESD procedure
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 2026SDU-QILU-4
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。